EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS

Chu Zhang iD, Hui Wang, Xianglei Chen, Yong Liu, Puen Jiang iD

PLOS One · 24.04.2025 · 20 (4) · e0321307

DOI: 10.1371/journal.pone.0321307 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 24.04.2025. Verfasst von Chu Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chizhou Aier Eye Hospital, Chizhou, Anhui, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Adverse Drug Reaction Reporting Systems, Sulfones, Dry Eye Syndromes. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To comprehensively assess the safety of Lifitegrast, a drug for dry eye disease, we conducted a comprehensive analysis of adverse event (AE) reports from the FDA Adverse Event Reporting System (FAERS). This retrospective study examined all AE reports submitted between Q3 2016 and Q2 2024, employing disproportionality analysis to identify safety signals associated with Lifitegrast. Out of a total of 13,326,934 AE reports indexed in the FAERS database, 12,393 listed Lifitegrast as the primary suspect drug. A total of 230 ocular AE signals were identified, with 104 of these AEs being detected by different analysis algorithms. Among these signals, 71 AEs were documented in the product insert of Lifitegrast, including but not limited to eye irritation, eye pain and eye swelling. AEs not mentioned in the drug labeling were identified, such as glaucoma and cataracts.AEs associated with Lifitegrast are more commonly observed in male patients and those aged over 65 years.The insights derived from this FAERS database analysis are significant for optimizing the use of Lifitegrast while minimizing potential side effects, thereby enhancing the safety of its clinical application.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PharmacovigilanceAdverse Drug Reaction Reporting SystemsSulfonesDry Eye SyndromesHumansMaleFemaleRetrospective StudiesMiddle AgedAgedAdultUnited StatesDatabases, FactualYoung AdultAdolescentUnited States Food and Drug AdministrationAged, 80 and overPhenylalanine

Substanzen

lifitegrastSulfonesPhenylalanine

Autor:innen und Institutionen

  • Chizhou Aier Eye Hospital, Chizhou, Anhui, China.
  • Nanling County Hospital of Traditional Chinese Medicine, Wuhu, Anhui, China.
  • Anhui Aier Eye Hospital, Hefei, Anhui, China.
  • The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

ORCID-Profile: Chu Zhang, Puen Jiang

Zitieren

APA

Zhang, C., Wang, H., Chen, X., Liu, Y., & Jiang, P. (2025). Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS. PLOS One, 20(4), e0321307. https://doi.org/10.1371/journal.pone.0321307

Vancouver

Zhang C, Wang H, Chen X, Liu Y, Jiang P. Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS. PLOS One. 2025;20(4):e0321307. doi:10.1371/journal.pone.0321307

BibTeX
@article{Zhang2025,
  author = {Zhang, Chu and Wang, Hui and Chen, Xianglei and Liu, Yong and Jiang, Puen},
  title = {Safety of lifitegrast: A real-world pharmacovigilance study based on FAERS},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {4},
  pages = {e0321307},
  doi = {10.1371/journal.pone.0321307}
}
Kostenlos starten →